Market Cap | 1.14B | P/E | 106.23 | EPS this Y | -36.50% | Ern Qtrly Grth | - |
Income | -76.43M | Forward P/E | -12.24 | EPS next Y | -12.60% | 50D Avg Chg | 11.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 37.00% |
Dividend | N/A | Price/Book | 4.20 | EPS next 5Y | - | 52W High Chg | -21.00% |
Recommedations | 1.80 | Quick Ratio | 16.81 | Shares Outstanding | 24.68M | 52W Low Chg | 233.00% |
Insider Own | 13.38% | ROA | -20.05% | Shares Float | 13.49M | Beta | - |
Inst Own | 85.07% | ROE | -29.30% | Shares Shorted/Prior | 1.91M/1.26M | Price | 49.93 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 204,851 | Target Price | 57.11 |
Oper. Margin | - | Earnings Date | May 13 | Volume | 127,404 | Change | -0.85% |
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Stifel | Buy | Apr 8, 24 |
Morgan Stanley | Equal-Weight | Apr 2, 24 |
BMO Capital | Outperform | Apr 2, 24 |
Stifel | Buy | Apr 2, 24 |
Raymond James | Outperform | Apr 1, 24 |
HC Wainwright & Co. | Buy | Apr 1, 24 |
HC Wainwright & Co. | Buy | Mar 22, 24 |
Stifel | Buy | Mar 12, 24 |
BMO Capital | Outperform | Feb 29, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Bitterman Kevin | Director Director | Jan 23 | Sell | 67.65 | 102,500 | 6,934,125 | 198,326 | 01/25/24 |
Bitterman Kevin | Director Director | Jan 10 | Sell | 64.00 | 20,000 | 1,280,000 | 786,160 | 01/12/24 |
Atlas Venture Fund X, L.P. | 10% Owner 10% Owner | Jan 10 | Sell | 64 | 50,000 | 3,200,000 | 786,160 | 01/12/24 |
ORBIMED ADVISORS LLC | Director Director | Dec 18 | Sell | 59.24 | 1,724 | 102,130 | 12/20/23 | |
ORBIMED ADVISORS LLC | Director Director | Dec 18 | Option | 38 | 1,724 | 65,512 | 1,724 | 12/20/23 |
Ashiya Mona | Director Director | Dec 18 | Sell | 59.24 | 1,724 | 102,130 | 12/20/23 | |
Ashiya Mona | Director Director | Dec 18 | Option | 38 | 1,724 | 65,512 | 1,724 | 12/20/23 |
Ashiya Mona | Director Director | Dec 14 | Sell | 56.75 | 433,200 | 24,584,100 | 224,405 | 12/15/23 |
ORBIMED ADVISORS LLC | Director Director | Dec 14 | Sell | 56.75 | 433,200 | 24,584,100 | 224,405 | 12/15/23 |
Bitterman Kevin | Director Director | Dec 12 | Sell | 61.76 | 76,064 | 4,697,713 | 806,160 | 12/14/23 |
Atlas Venture Fund X, L.P. | 10% Owner 10% Owner | Dec 12 | Sell | 61.76 | 190,163 | 11,744,467 | 806,160 | 12/14/23 |
ORBIMED ADVISORS LLC | Director Director | Dec 12 | Sell | 58.95 | 134,200 | 7,911,090 | 727,807 | 12/14/23 |
Ashiya Mona | Director Director | Dec 12 | Sell | 58.95 | 134,200 | 7,911,090 | 727,807 | 12/14/23 |
Khara Rahul | General Counsel General Counsel | Nov 14 | Sell | 50.79 | 4,900 | 248,871 | 11/15/23 | |
Khara Rahul | General Counsel General Counsel | Nov 14 | Option | 14.69 | 4,900 | 71,981 | 4,900 | 11/15/23 |
Khara Rahul | General Counsel General Counsel | Nov 03 | Sell | 50 | 100 | 5,000 | 11/07/23 | |
Khara Rahul | General Counsel General Counsel | Nov 03 | Option | 14.69 | 100 | 1,469 | 100 | 11/07/23 |
Atlas Venture Fund X, L.P. | 10% Owner 10% Owner | Sep 14 | Sell | 53.14 | 357,449 | 18,994,840 | 1,593,785 | 09/18/23 |
Savage William Jacob | Chief Medical Office.. Chief Medical Officer | Aug 21 | Option | 2.65 | 3,000 | 7,950 | 3,000 | 08/22/23 |
Atlas Venture Fund X, L.P. | 10% Owner 10% Owner | Aug 14 | Sell | 52.92 | 359,000 | 18,998,280 | 882,224 | 08/16/23 |
MacDonald Brian Richard | Chief Innovation Off.. Chief Innovation Officer | Jun 28 | Sell | 47.11 | 15,124 | 712,492 | 12,276 | 06/30/23 |
Leonard Braden Michael | 10% Owner 10% Owner | Apr 11 | Buy | 1.41 | 955,000 | 1,346,550 | 5,000,000 | 04/13/22 |